Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.57 |
| ▸ | BACE1 | P56817 | 4/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10795431 | 0.87 | SIGMAR1 (0.60) | ACHEBACE1DRD4SIGMAR1BCHE | |
| SCHEMBL4870804 | 0.86 | GRIN2A (0.54) | ACHECCR3GRIN2AGRIN2BCARM1 | |
| SCHEMBL4869777 | 0.83 | ACHE (0.41) | ACHEBACE1DRD4SIGMAR1BCHE | |
| SCHEMBL4873718 | 0.82 | PTGIR (0.56) | ACHEBACE1SIGMAR1GRIN2B | |
| Maleic Acid SCHEMBL10799180 | 0.80 | DRD2 (0.54) | ACHEDRD4SIGMAR1BCHEDRD2 | |
| Fumaric Acid SCHEMBL10799186 | 0.80 | DRD2 (0.54) | ACHEDRD4SIGMAR1BCHEDRD2 | |
| SCHEMBL10797896 | 0.80 | CARM1 (0.52) | ACHEBACE1DRD4SIGMAR1BCHE | |
| SCHEMBL4866350 | 0.80 | L3MBTL1 (0.54) | DRD4SIGMAR1 | |
| SCHEMBL6875117 | 0.79 | SIGMAR1 (0.49) | SIGMAR1GRIN2AGRIN2B | |
| SCHEMBL10797797 | 0.78 | ACHE (0.54) | ACHEBACE1DRD4SIGMAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408067-B2 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK + CO., INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1467986-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062224-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | CHRNG, CHRNA4, CHRNB4 | ACHE 25/4885BACE1 3424/4885DRD4 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.